Human respiratory syncytial virus medical therapy

Human respiratory syncytial virus Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Human Respiratory Syncytial Virus from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Human respiratory syncytial virus medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Human respiratory syncytial virus medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Human respiratory syncytial virus medical therapy
CDC on Human respiratory syncytial virus medical therapy
Human respiratory syncytial virus medical therapy in the news
Blogs on Human respiratory syncytial virus medical therapy
Directions to Hospitals Treating Human respiratory syncytial virus
Risk calculators and risk factors for Human respiratory syncytial virus medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Ribavirin, a broad-spectrum antiviral agent, was once employed as adjunctive therapy for the sickest patients; however, its efficacy has been called into question by multiple studies, and most institutions no longer use it.

Treatment is otherwise supportive care only with fluids and oxygen until the illness runs its course.